Picture of Amicus Therapeutics logo

FOLD Amicus Therapeutics Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapNeutral

Momentum

Relative Strength (%)
1m-17.36%
3m-22.66%
6m-22.07%
1yr-21.9%
Volume Change (%)
10d/3m+9.83%
Price vs... (%)
52w High-20.86%
50d MA-9.57%
200d MA-6.92%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)123.79
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value21.26
Price to Tang. Bookn/a
Price to Free Cashflown/a
Price to Sales8.53
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-14.94%
Return on Equity-107.04%
Operating Margin-22.82%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Amicus Therapeutics EPS forecast chart

Profile Summary

Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
February 4th, 2002
Public Since
May 31st, 2007
No. of Shareholders
17
No. of Employees
517
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
295,382,614

FOLD Share Price Performance

Upcoming Events for FOLD

Q1 2024 Amicus Therapeutics Inc Earnings Release

Amicus Therapeutics Inc Annual Shareholders Meeting

Q2 2024 Amicus Therapeutics Inc Earnings Release

Similar to FOLD

Picture of 89bio logo

89bio

us flag iconNASDAQ Global Market

Picture of Abivax SA logo

Abivax SA

us flag iconNASDAQ Global Market

Picture of AC Immune SA logo

AC Immune SA

us flag iconNASDAQ Global Market

Picture of Acrivon Therapeutics logo

Acrivon Therapeutics

us flag iconNASDAQ Global Market

Picture of Adagene logo

Adagene

us flag iconNASDAQ Global Market

FAQ